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 Abstract 
 Objectives. This article presents an overview of the current literature on biological markers for alcoholism, including mark-
ers associated with the pharmacological effects of alcohol and markers related to the clinical course and treatment of 
alcohol-related problems. Many of these studies are well known, while other studies cited are new and still being evaluated. 
 Methods. In this paper we fi rst describe known biomarkers of alcohol-related disorders, review their features and the prob-
lems involved in their use. We then consider future developments on biomarkers and their possible impact on the fi eld. 
 Results. More recent fi ndings cited include the work on type 7 adenylcyclase (AC) polymorphism and its lower expression 
levels in female alcoholics. Neuroimaging studies involving biomarkers have also reported brain volume reductions of gray 
and white matter, including amygdala and subcortical regions in alcoholic patients, while a high association between the 
copy number variations (CNVs) in 6q14.1/5q13.2 and alcohol dependence has more recently been identifi ed in genetic 
studies.  Conclusions . In addition to their possible importance for diagnosis, biomarkers may have utility for predicting 
prognosis, progression of the disorder, the development of new treatments, and monitoring treatment effects. Although 
such fi ndings should be verifi ed in independent studies, the search for new biomarkers is continuing. Several potential 
candidate biomarkers have been found recently in blood, imaging, and genetic studies with encouraging results. 
 Key words:  alcohol ,  biochemical markers ,  abuse ,  alcohol dependence ,  alcohol use disorder 
 Introduction 
 Alcohol (ethanol) is one of the most widely mis-
used drugs in the world. Humans respond to low 
doses of ethanol with euphoria, but with disinhibi-
tion, incoordination and lethargy at high doses. 
Alcohol abuse and alcohol dependence signify alco-
hol use disorders characterized by chronic heavy 
drinking, culminating in serious adverse outcomes 
and loss of control. Alcohol dependence is charac-
terized by an unhealthy drive to drink alcohol that 
leads to an inability to control intake on any given 
occasion and an increasing tolerance to alcohol ’ s 
effects. The identifi cation of biochemical substances 
in the body suggesting the repeated use of heavy 
doses of alcohol as possibly part of an alcohol use 
disorder and the identifi cation of genetic suscepti-
bility factors for alcoholism (i.e.  “ biomarkers for 
alcoholics ” ) will provide important tools for future 
investigation. 
 The goal of this paper is to provide a guide to the 
optimal application of biomarkers for heavy drinking 
and alcohol use disorders, and to facilitate objective 
and quantitative data gathering in both clinical and 
research settings. 
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ethanol withdrawal. Chronic alcohol consumption 
may also augment the sensitivity to NMDA by 
increasing the density of NMDA receptors, thereby 
increasing biosynthesis or release of glutamate. 
Thus, the effects of ethanol on calcium homeostasis 
can have an important impact on the clinical fea-
tures of alcoholism. 
 Therapeutic studies in alcoholics 
 The opioid receptor antagonists naltrexone and 
nalmefene have been shown to be effective in reducing 
alcohol consumption in both animal and human stud-
ies. Naltrexone ’ s propensity to reduce alcohol intake 
may be negatively correlated with baseline beta-
endorphin levels as mu-opioid receptor antagonists 
attenuate alcohol consumption. Nalmefene also works 
as an opioid receptor antagonist and is helpful in the 
treatment of alcohol dependence. Nalmefene has a 
longer half-life than naltrexone, better bioavailability, 
and a more favourable tolerance profi le in achieving 
its benefi t. Because alcohol is believed to activate the 
brain reward system by increasing the release of beta-
endorphin, an endogenous opioid receptor ligand, it 
is possible that some of the rewarding and pleasant 
effects of alcohol related to this physiological effect 
promote drinking behaviour. Although the precise 
mechanisms underlying the actions of nalmefene 
remain to be elucidated, endogenous opioid peptides 
as well as metabolic by-products of ethanol (e.g., tet-
rahydroisoquinolines and beta-carbolines) may medi-
ate these effects and may also involve interactions 
between cannabinoids and the opioid receptor system. 
These rewarding and pleasant effects are potentially 
associated with both internal and external drinking 
cues. Analogous to the concept of negative rein-
forcement or relief craving (euphoria and disinhibi-
tion), the latter type of craving could theoretically be 
classifi ed as positive craving. In the fi rst case alcohol 
acts as a positive reinforcer, in the second instance it 
serves as a negative reinforce (Mann et al. 2009). 
 A second medication that has been shown to 
decrease alcohol use and alcohol problems in alco-
holics is acamprosate. This compound works as an 
excitatory amine antagonist, mainly through gluta-
mate but it is also a GABA stimulant. It is believed 
that this action reduces alcohol craving and pro-
motes abstinence. While the precise benefi cial mech-
anisms of action for treating alcoholism are not 
completely understood, the relationship of the glu-
tamatergic system and the mechanism of action of 
acamprosate serves as one example of how our 
understanding of the pharmacological effects of 
alcohol may offer important new leads for develop-
ing or modifying alcoholism treatments. 
 Pharmacological effects of alcohol 
 Many neurochemical systems have been implicated 
in the biology of alcohol intoxication, but two sys-
tems are the most relevant: (1) gamma-aminobutyric 
acid (GABA) and its receptors; (2) glutamate and the 
 N -methyl- D -aspartic acid (NMDA) receptor ( α glu-
tamate receptors) ’ and the opioid systems (Addison 
and Kurtz 1986). GABA receptors include ion-selec-
tive and ligand-gated ion channels, while GABA itself 
is the major inhibitory neurotransmitter in the brain 
that interacts with a family of receptors that recog-
nize anxiolytic and sedative drugs. For example, ben-
zodiazepines, which share bio-behavioural properties 
with alcohol, enhance Cl  –  transport through GABA A 
receptors. Drugs that simulate the effect of GABA 
enhance and prolong the behavioural effects of alco-
hol, whereas drugs opposing the effect of GABA 
antagonize alcohols effects. In animal studies, benzo-
diazepine receptor antagonists have been shown to 
block many alcohol-induced cognitive, behavioural 
and neurophysiological effects of ethanol. 
 Several lines of evidence implicate opioid peptides, 
such as beta-endorphin (an endogenous opioid 
receptor ligand), in both the perception of the 
rewarding effects of ethanol and in the risk for devel-
oping alcoholism. Alcohol is believed to activate the 
brain reward system, especially in the mesolimbic 
dopamine system, in part by increasing beta-endor-
phin release. The direct mechanism of alcohol ’ s 
action on dopamine release in the ventral tegmental 
area (VTA) is intriguing and has been widely inves-
tigated. Recent patch clamp studies suggest that 
alcohol excites VTA dopamine neurons, partly by 
increasing ongoing opioid-mediated suppression of 
local GABAergic inhibition. 
 Glutamate, the major excitatory neurotransmitter 
in the brain, is also believed to be involved in alco-
hol-induced intoxication and behaviour changes. 
Electrophysiological studies in animals show that 
antagonizing NMDA receptors produces similar 
behavioural effects to alcohol. 
 Tolerance to both the sedative and intoxicating 
effects of alcohol is partly due to a compensatory 
decrease in GABA-mediated inhibition in the brain. 
Alcohol-induced alterations in the function of the 
GABA A receptor Cl 
 –  channels that remain after ces-
sation of drinking are believed to contribute to the 
clinical features associated with ethanol withdrawal. 
Decreased GABA-mediated inhibition of the neu-
ronal functions and increased activity of NMDA 
receptors may help explain important characteris-
tics of alcohol withdrawal. Hypersensitive, NMDA-
induced calcium fl ux occurs following chronic 
alcohol exposure and may contribute to the hyper-
excitability and seizures that can be seen during 
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metabolizing enzymes, the sensitivity to alcohol and 
impulsivity and related personality characteristics, as 
discussed further below in the section on trait mark-
ers of risk. 
 Signifi cance of biomarkers for studying 
alcoholism 
 Biomarkers that relate to recent heavy drinking 
(state markers) have several possible applications, 
namely as (1) diagnostic tools; (2) screening tools; 
or (3) for use in early or pre-symptomatic identifi ca-
tion. Any biological characteristic that can be objec-
tively measured and reliably indicates a predisposition 
to a specifi c condition, or the presence or progress 
of a pathological state can be regarded as a bio-
marker (Atkinson et al. 2001). Biochemical state 
markers for alcoholism can provide clinicians with 
objective measures of patient ’ s recent drinking pat-
terns, whether heavy drinking or a more modest 
intake. The availability of state markers for alcohol-
ism may also facilitate optimal treatment(s). Clini-
cians would be greatly assisted by biological markers 
that accurately refl ect both the degree of problem-
atic drinking  and the presence of a genetic predis-
position to alcoholism. Not surprisingly, considerable 
recent effort has been expended on developing 
objective, biologically based, and easily measured 
biomarkers for alcoholism. 
 Currently, there are no biomarkers that can directly 
identify alcoholism. Much of state marker research 
in studies of alcoholics has been focused on fi nding 
clinically useful alcohol consumption biomarkers or 
markers that can detect the timing and intensity of 
an individual ’ s alcohol use. The identifi cation of 
additional state markers to assess the effectiveness of 
treatments would be of considerable value. 
 On the other hand, trait markers are biochemical 
markers that reveal some possible genetic links 
between the inherited risk for heavy drinking and the 
consequent alcohol problems. Trait markers must be 
clinically validated by testing  “ at risk ” individuals 
before the onset of alcoholism. Marker-positive 
patients would become prime candidates for preven-
tion programs since early warning may make it pos-
sible to avoid alcoholism. Individuals with a family 
history of alcoholism are 3 – 5 times more likely to 
develop alcoholism than are individuals with no such 
family history. One important feature of trait bio-
markers of alcoholism is to provide information 
regarding a person ’ s inherited risk of alcoholism. A 
good biomarker, whether state or trait, should be 
sensitive (i.e. accurate for most if not all drinkers) 
and specifi c (i.e. linked to alcohol use but not to 
other psychiatric conditions). The biomarker tests 
 Comorbidity of alcoholism and psychiatric 
disorders 
 As with all complex diseases, alcoholism can be 
regarded as a clinical syndrome resulting from a 
combination of multiple risk factors; consequently 
individuals can present with diverse sets of symp-
toms and severity of disease (Hines et al. 2005). For 
example, the prevalence of psychiatric symptoms is 
higher in individuals who drink more heavily and 
more regularly, i.e. patients with alcohol dependence, 
compared to those with a diagnosis of alcohol abuse. 
In the National Comorbidity Study, 29.2% of 
respondents with alcohol dependence experienced 
either an independent or a substance-induced mood 
disorder within the past 12 months of their assess-
ment, a rate that was 3.9 times higher than those 
who were not alcohol dependent. Bipolar disorder 
over the previous year was seen in 1.9% of the 
respondents with alcohol dependence, a rate 6.3 
times greater than non-alcoholics (Regier et al. 1990; 
Feinman and Dunner 1996; Cornelius et al. 2003). 
Furthermore, among people with alcohol depen-
dence, 36.9% met the criteria for an anxiety disorder 
during the previous year, including 11.6% with gen-
eralized anxiety disorder (GAD), 3.9% with panic 
disorder, and 7.7% with PTSD, all representing 
higher rates than those seen in the general popula-
tion. Further, alcohol- and substance-use disorders 
are very common in patients with schizophrenia. 
The Epidemiologic Catchment Area (ECA) study 
(Regier et al. 1990) reported that 47% of patients 
with schizophrenia had a lifetime history of a sub-
stance-use disorder and that 34% of these patients 
have a lifetime diagnosis of an alcohol-use disorder 
(Le Fauve et al. 2004). 
 Genetic infl uences in alcoholism 
 Like other complex genetic disorders, alcohol use 
disorders are heterogeneous in their clinical presen-
tation and their course. Combined, genetic factors 
explain an estimated 60% of the variance, interacting 
with environmental factors that contribute to the 
remaining 40% (Schuckit 1999; Kendler et al. 
2003). Genetic factors that affect susceptibility to 
alcoholism may be related to certain components of 
alcoholism, such as alcohol metabolism, personality, 
cognitive function, and neurophysiology. A classical 
approach for identifying alcohol susceptibility genes 
is to focus on particular features of alcoholism 
dependence, i.e. intermediate phenotypes that likely 
infl uence susceptibility to alcohol dependence, 
also known as endophenotypes (Hines et al. 2005). 
These studies have often been able to identify genes 
that impact the alcoholism risk, including alcohol 
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consumption patterns provide essential information 
regarding the extent of a patient ’ s alcohol use, the 
risk of having or developing alcoholism, and related 
alcohol-related adverse effects (Peterson 2004 –
 2005). More specifi cally, biomarkers that can esti-
mate the amount of alcohol consumed over various 
periods of time could assist clinicians in verifying 
vital information such as the time of the last drink 
and the current pattern of alcohol use (harmful, haz-
ardous, or non-hazardous). 
 Alcohol consumption biomarkers 
 Current biomarkers for alcohol consumption include 
carbohydrate-defi cient transferrin (CDT), gamma-
glutamyl transferase (GGT), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), mean 
corpuscular volume (MCV), and direct measures of 
should be noninvasive, easy-to-perform, inexpensive, 
rapid, have stable values, and especially should allow 
reproducibility in laboratories worldwide. Indeed, 
numerous biomarkers of alcohol use have been iden-
tifi ed that can measure patterns of previous alcohol 
use from hours to days and weeks, but with variable 
accuracy (Table I). 
 State markers for alcoholism 
 State markers can be used for diagnosis or screening, 
prognosis, determining disorder stage, or for moni-
toring the effectiveness of an intervention. Unfortu-
nately, state markers are currently limited to 
measuring patterns of alcohol consumption rather 
than directly measuring the entire spectrum of alco-
holism including dependence symptoms and evi-
dence of harmful use. Despite this limitation, alcohol 
 Table I. Possible state and trait markers for alcoholics. 
 Biomarker Remarks Sensitivity Specifi city Possible or current use
 State markers (recent drinking activity) 
GGT (gamma-glutamyltransferase) Early indicator of chronic heavy 
drinkers, liver disease
61 n/a Chronic alcohol abuse
ALT (alanine aminotransferase) More useful for liver disease; AST/ALT 
ratio: heavy alcohol consumption
n/a n/a Chronic alcohol abuse
AST (aspartate aminotransferase) 56 n/a Chronic alcohol abuse
MCV (mean corpuscular volume) Less useful, but high level is maintained 
for several months after stop drinking
47 n/a Heavy alcohol use
Beta-Hex ( N -acetyl-b-hexosaminidase) Elevated in heavy drinkers; diffi cult to 
assay
94 91 Heavy alcohol use
CDT (carbohydrate-defi cient 
transferrin)
Higher amounts of CDT in heavy 
drinkers; highly specifi c to alcohol 
consumption; diffi cult to measure
26 – 83 92 Heavy alcohol use
SIJ (plasma sialic acid index of apoJ) Sialilated ApoJ decrease after alcohol 
consumption
n/a n/a
TSA (total serum sialic acid) Elevated in alcoholics; long-term 
elevation even during abstinent
n/a n/a
5-HTOL (5-hyderoxytryptophol) 24-h biomarker; useful in forensic 
toxicology
n/a n/a Monitoring sobriety
FAEE (fatty acid ethyl esters) 24-h biomarker; distinguishable social 
drinkers from heavy drinker or 
alcoholics
100 90 Recent heavy alcohol use
EtG (ethyl glucuronide) 24-h (blood) or 36-hour (urine) 
biomarker; detectable in other body 
fl uids tissue or hair
n/a n/a Monitoring sobriety; 
forensics
WBAA (whole blood-associated 
acetaldehyde)
Alcohol specifi c biomarker; Hb-bound 
acetaldehyde accumulate in RBC over 
120 days
100 95 Recent alcohol 
consumption at all 
levels; monitoring 
abstinence
Salsolinol Better marker for chronic alcohol 
consumption (blood); no difference 
between alcoholics and nonalcoholics 
(brain)
n/a n/a Chronic alcohol 
consumption
CPK (creatine phosphokinase) Elevated in alcoholics(hallucination, 
delirium)
n/a n/a
Fisher ratio (BCAA/AAA) Low level in alcohol dependence n/a n/a
MAO-B (monoamine oxidase B) Low level in hazardous/harmful 
alcohol use
n/a n/a Recent alcohol 
consumption; 
monitoring success of 
treatment
(Continued )
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body (Wurst et al. 2003). Fatty acid ethyl esters 
(FAEE) are known to be a direct alcohol intake marker 
and are often investigated in hair and skin surface 
samples. The highest FAEE/sebum are detected 7 – 9 
days after the days of high alcohol consumption 
(Gonz á lez-Ill á n et al. 2011). Phosphatidylethanol 
(PEth) is a glycerophospholipid homologue contain-
ing an amino-alcohol by phospholipase D. Since the 
formation of PEth is specifi cally dependent on etha-
nol, the diagnostic specifi city of PEth as an alcohol 
biomarker is theoretically 100% and its half-life in 
blood is approximately 4 days. The amount of alcohol 
consumed highly correlates with the blood concentra-
tion of PEth; thus, PEth appears to be a more sensitive 
indicator of alcohol consumption than traditional 
alcohol markers, such as CDT, GGT, and MCV 
(Isaksson et al. 2011). Recently, novel serum markers 
have been identifi ed as possible candidate markers for 
alcoholism or at least heavy alcohol consumption. Pig-
ment epithelial-derived factor (PEDF) has been found 
in moderate to heavy habitual drinkers, but not in 
healthy subjects with no drinking history (Sogawa et 
al. 2011). Elevation of N-terminal pro-BNP (NtBNP), 
a circulating neurohormone which is also a marker of 
cardiac dysfunction, has been found in alcoholic 
patients. An elevated level of NtBNP was reversed and 
signifi cantly decreased after therapy for withdrawal 
symptoms (Hoefer et al. 2011). 
 Use of alcohol consumption biomarkers in 
clinical practice 
 In current clinical practice, the diagnosis of alcohol-
related disorders usually depends on patient self-
reporting. While the veracity of self-reporting is a 
relatively accurate measure of alcohol use (Babor 
et al. 1989), combining biological markers with per-
formance of the alcohol use disorders identifi cation 
test (AUDIT) questionnaire can be helpful in clini-
cal settings. A positive predictive value (PPV) of 
17.3% for an AUDIT score 8 or more in the detec-
tion of withdrawal, increased to 47.1% when used in 
combination with at least two other abnormal bio-
logical markers including MCV, AST, ALT, and 
GGT (Dolman et al. 2005). 
ethanol in blood and breath, and ethanol ’ s metabo-
lites. Of these tests, CDT appears to be the most sen-
sitive and specifi c single test for detecting more recent 
moderate to heavy alcohol intake ( ∼ 7 – 10 drinks a 
day). The CDT test and assay are highly standardized, 
automated and inexpensive; consequently, it is com-
monly used in clinical practice. When used alone, 
these tests are only moderately sensitive, but their 
combined use greatly improves sensitivity without a 
marked decrease in specifi city (Hietala et al. 2006). A 
wide range of medications affect GGT, particularly 
those that induce the microsomal enzymes (Table I). 
A variety of hepatic or biliary conditions can affect 
GGT, including hepatic congestion in cardiac failure. 
Disorders of other body sites where GGT is found can 
also affect GGT levels (e.g., diabetes and pancreatitis) 
(Conigrave et al. 2003). 
 AST/ALT and MCV are often used in clinical 
practice to detect chronic heavy drinking, but are 
much less sensitive and specifi c for detecting heavy 
alcohol use. Aminotransferases are less sensitive than 
GGT in the detection of excessive alcohol consump-
tion. The AST/ALT ratio appears to be a useful index 
for distinguishing non-alcoholic steatohepatitis 
(NASH) from alcoholic liver disease (a ratio of    1 
suggests NASH and values    2 are strongly sugges-
tive of alcoholic liver disease (Sorbi et al. 1999). How-
ever, the AST/ALT ratio is thought to be indicative 
advanced alcoholic liver disease rather than heavy 
alcohol consumption (Nyblom et al. 2004). Since the 
life-span of a red blood cell is about 120 days, it may 
take several months for changes in drinking to be 
refl ected in MCV levels (Hasselblatt et al. 2001). Sus-
tained and regular excessive drinking is important for 
elevating MCV levels (Meerkerk et al. 1999) and the 
levels may continue to rise upon cessation of drinking 
in alcohol dependence (Monteiro et al. 1986). The 
half-lives of plasma GGT, MCV and CDT are, 
respectively, 4 weeks, 2 – 3 months and 14 – 16 days. 
 Direct measurement of ethanol is a widely used 
measure of acute intake, but its relatively short half-
life (a few hours) limits its usefulness. Ethyl glucuronide 
(EtG) and ethyl sulfate (EtS), direct metabolites of 
ethanol, can indicate even a minor intake of alcohol 
up to 80 h after alcohol has been eliminated from the 
 Biomarker Remarks Sensitivity Specifi city
Trait markers (genetic predisposition)
AC (adenylyl cyclase) Not specifi c to alcoholic (c.f. marijuana and other drug use) n/a n/a
GABA (gamma-aminobutyric acid) Low level in alcohol dependence n/a n/a
Dopamine Low level even after abstinent for 7 years n/a n/a
b-endorphin Low level in alcohol dependence n/a n/a
Serotonin Higher serotonin transporter activity than non- alcoholics n/a n/a
 Refs: Peterson K. Alcohol Res Health 2004/2005;28:30 – 37; Saito et al. Alcohol Alcoholism 194;29(Suppl 1):133 – 135; Snell et al. 
Alcoholism: Clin Exp Res 2012;36:322 – 341. 
Table I. (Continued )
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none of these markers singularly has adequate sen-
sitivity and specifi city for screening, their diagnostic 
utility increases when measured as part of a panel of 
markers. These latter markers are also durably depos-
ited in hair (fi fth month of pregnancy in total) and 
may also be measured in mothers or newborns ’ hair. 
Indeed, the retrospective detection of alcohol con-
sumption during pregnancy is an important part of 
the diagnosis of foetal alcohol syndrome and foetal 
alcohol spectrum disorders. Ethanol metabolites, in 
conjunction with the AUDIT, were most likely to 
detect drinking in 2nd-trimester pregnant women in 
a hospital setting (Wurst et al. 2008). 
 Workplace and criminal justice settings 
 A survey of aftercare programs in the US for health 
care professionals with substance abuse problems 
found that a range of alcohol biomarkers are being 
used to monitor abstinence (Hayes et al. 1989). 
Additionally, there is some evidence that CDT is a 
complementary test to the AUDIT in screening for 
alcohol abuse disorders among transportation workers 
(Hermansson et al. 2000). Similarly, there is a consid-
erable need for better alcohol use disorders diagnostic 
tools in criminal justice settings. One study found that 
under-reporting was common in  “ driving while 
impaired ” (DWI) offenders (Lapham et al. 2004). 
 Others 
 It was reported that ethanol induces elevation of Fas/
Apo-1 mRNA and activated caspase 3 (Saito et al. 
1999; Cheema et al. 2000); on the other hand, in 
neuronal cells, a biphasic response to the Ca 2   -
channel (NMDA receptor) depends on the duration 
of ethanol ingestion (Kumari and Ticku 2000). 
Short-term exposure attenuates the channel activity; 
however, long-term exposure up regulates the num-
ber of channels, which in turn increases the intracel-
lular Ca 2   -concentration. Using neuronal and glial 
cell cultures, increased expression of annexin IV, a 
calcium and phospholipid binding protein, has been 
found in relation to heavy ethanol exposure (Ohkawa 
et al. 2002) and annexin IV may be a specifi c marker 
for the effects of ethanol. The augmented expression 
of annexin IV in specimens from alcoholics suggests 
that it may be involved in the recovery from the dam-
age caused by alcohol. 
 Trait markers for alcoholism 
 Trait markers for alcoholism could potentially help 
identify those individuals genetically predisposed 
to develop alcoholism. Trait markers should be 
 Recovery programs 
 Al t hough biomarkers are not widely used in special-
ized alcohol treatment programs, they may be par-
ticularly useful in detecting relapse. CDT is 
signifi cantly more sensitive than GGT in detecting 
relapses. Chen et al. reported that CDT combined 
with GGT was successful in monitoring relapse in 
inpatient alcoholics (Chen et al. 2003). Due to their 
ability to detect small amounts of alcohol, urinary 
EtG/EtS can potentially monitor relapse in patients 
in active treatment programs. However, PEth mea-
surement in whole blood is a more sensitive bio-
marker than serum CDT for the detection of relapse 
drinking because the PEth test can detect lower con-
sumption levels. The half-lives for total PEth and for 
CDT (the relative disialotransferin) are estimated to 
be 3.5 – 9.0 days (mean 6.1) and 8.5 – 15 days (mean 
12.6), respectively (Helander et al. 2012). 
 Primary care 
 Because heavy alcohol use can cause or aggravate 
numerous common medical conditions, biomarkers 
for heavy alcohol use could yield vital information to 
primary care providers. CDT levels have been found 
to be useful in detecting and/or confi rming high-risk 
alcohol use in patients treated for type 2-diabetes and 
hypertension in a primary care setting (Fleming et al. 
2004). The CDT test, in addition, to patient self-re-
port may provide an economic healthcare benefi t by 
identifying a larger number of heavy drinkers in the 
primary care population. The positive net benefi t (cost 
savings) can be attributed to improved detection and 
intervention in cases of heavy drinking and the ability 
of intervention(s) to reduce the occurrence of expen-
sive medical and legal events (Dillie et al. 2005). 
 Hospital settings 
 Alcoholism is often associated with medical compli-
cations in the clinical course of patients with trauma 
or who are undergoing surgery (Miller et al. 2006; 
Fleming et al. 2009). CDT has been found to be an 
accurate marker for detecting patients at-risk for 
alcohol-related surgical complications, alcohol with-
drawal, an increased risk of complications, and a 
prolonged ICU stay after severe trauma (Spies et al. 
1998). Recently, fatty acid ethyl esters (FAEEs) in 
meconium, particularly ethyl linoleate and ethyl AA, 
emerged as reliable, direct biological markers for 
establishing gestational ethanol exposure among 
recently delivered babies. Among the minor non-
oxidative products of ethanol metabolism, ethyl 
glucuronide (EtG) and ethyl sulfate (EtS) may also 
be measured (Lamy and Thibaut 2011). Although 
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1960; Dick et al. 2006a). While there may be genes 
that directly or indirectly impact the susceptibility 
for developing alcoholism, it is more likely that there 
are a larger number of genes that affect intermediate 
characteristics, or endophenotypes, that then affect 
alcoholism  “ risk ” . Because genetically infl uenced 
characteristics (endophenotypes) are presumed to be 
closer to the genotype than the features of the disease 
syndrome itself, endophenotypes represent a poten-
tially powerful tool in psychiatric diagnosis, as well 
as a strategy to explore the genetic basis of complex 
illnesses such as alcoholism, although this view has 
been contested (Flint and Munafo 2007). 
 Numerous endophenotypes have been proposed 
for alcoholism. These include a person ’ s low level of 
response (or low sensitivity) to alcohol (i.e. a low 
LR) and personality features such as impulsivity, 
novelty-seeking and disinhibition. Also included are 
other major psychiatric disorders (primarily schizo-
phrenia and bipolar disorder), alcohol craving, the 
opioid peptide system, and characteristics of at-risk 
populations derived from electrophysiological and 
neuroimaging assessments (Winokur et al. 1996; 
D ’ Souza et al. 2006; Barr et al. 2007). Endopheno-
types potentially possess features desired in trait bio-
markers, including specifi city and state-independence; 
however, highly reproducible and easily measurable 
endophenotypic tests are currently lacking. Further-
more, several proposed alcoholism endophenotypes 
may also be confounded by the diagnosis of other 
co-occurring psychiatric disorders, rendering them 
more complicated diagnostically than alcoholism 
itself. Despite these obstacles, the endophenotypic 
strategy has been used to uncover potential trait bio-
markers as well as candidate genes involved in the 
aetiology of alcoholism. Other approaches to this 
problem include neurochemistry (primarily second 
messengers and neurotransmitters), neuroimaging, 
and electrophysiological analysis of at-risk popula-
tions for alcoholism, such as the children of alcohol-
ics (COA). 
 Biochemical measures 
 Using the defi nition of an endophenotype, a trait 
marker must be: (1) heritable (co-segregates with the 
disease within families and represents the genetic 
liability among non-affected relatives of subjects); 
(2) associated with the disease in the general popula-
tion; (3) state independent; (4) measurable; (5) aas-
sociated with the causal pathway of the disease; and 
(6) expected to be genetically less complex. Ratsma ’ s 
group examined fi ve neurotransmitters as potential 
markers for alcoholism vulnerability (Ratsma et al. 
2002). Two markers were identifi ed: namely, 
increased basal activity of the serotonin transporter 
heritable, associated with alcoholism in the general 
public and be present before alcoholism develops 
(Schuckit 1986). Ideally, a trait biomarker should 
share many of the same characteristics required of 
an ideal state biomarker: specifi c to the illness, easy 
to measure, reproducible, not be harmful to the indi-
vidual, and be cost effective. 
 Clinical signifi cance of trait biomarkers 
 Trait biomarkers could be useful in estimating the 
risk of developing alcoholism and, potentially, for 
predicting the course of the illness. Initially, knowl-
edge of alcoholism susceptibility might facilitate 
early diagnosis (McCaul et al. 1991). Furthermore 
this information might have a signifi cant infl uence 
on preventing alcoholism. For example, if the indi-
vidual is an adolescent, identifying a trait related to 
the potential development of later alcohol problems 
might encourage the initiation of parental or school 
preventive actions, both of which have demonstrated 
some effectiveness in preventing the start of sub-
stance use (McCaul et al. 1990). Knowledge of trait 
biomarkers could also affect selection of treatment 
strategies, particularly the intensity of treatment and 
its timing, by providing information about the sever-
ity or prognosis of the illness. They also may assist 
in identifying/subtyping different classes of alcohol-
ism leading to personalized treatment options. One 
example of the benefi ts of using trait markers comes 
from the PREDICT Study being conducted in Ger-
many (Mann et al. 2009). Here, biomarkers (fMRI, 
PET, genetic analysis) are used to divide alcoholics 
into two types: relief craving/drinkers and reward 
craving/drinkers. These two subtypes are then used 
in the evaluation of the treatment effi cacy of naltrex-
one and acamprosate (Mann et al. unpublished 
observations). One arm of the study examines 
whether variation in the mu-opioid receptor gene 
 OPRM1, which is associated with enhanced alcohol 
consumption, predicts naltrexone effi cacy (Oslin et 
al. 2003).  OPRM1 may be a trait biomarker useful 
for both subtyping alcoholics and predicting the effi -
cacy of anti-relapse agents. Similarly, a  GATA4 gene 
polymorphism may be useful in helping to predict 
the response to acamprosate (Kiefer et al. 2010). 
 Approaches to trait biomarker discovery 
 There are no trait biomarkers for alcoholism in rou-
tine clinical use today, mainly because of the com-
plexity of the illness. Beginning with Jellinek (1960) 
various subtype classifi cation systems of alcoholics 
have been proposed, refl ecting clinical recognition of 
the heterogeneous nature of the disease (Jellinek 
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period in which developing  “ top down ” cognitive 
control processes compete with earlier  “ bottom up ” 
motivational processes (Casey and Jones 2010). The 
 “ top down ” processes important for alcoholism vul-
nerability include resisting temptation and delaying 
immediate gratifi cation for more long-term goals; 
 “ bottom up ” processes involve motivational incen-
tives in the environment that might be more respon-
sible for risk-taking and novelty-seeking behaviour 
(Finn 2002). 
 Electrophysiology 
 Numerous EEG studies of at-risk for alcoholism 
populations have described potential electro-
physiological trait biomarkers for alcoholism (Porjesz 
et al. 1998b). Most notably, electrophysiological 
endophenotypes have been explored to identify genes 
involved in alcoholism predisposition (Dick et al. 
2006b, among others). Based on the observation that 
resting EEG beta power is highly heritable and is 
increased in alcoholics and the offspring of male 
alcoholics, linkage and linkage disequilibrium analy-
ses were conducted. A strong association between the 
resting beta frequency, and GABRA2, a gamma-
aminobutyric acid (GABA A ) receptor gene on chro-
mosome 4, in alcoholism was subsequently discovered 
(Dick et al. 2004; Edenberg et al. 2004). Increased 
resting beta power has been hypothesized to repre-
sent an overall CNS disinhibition/hyperexcitability, 
which might lead to increased alcohol use for its 
normalizing effect (Begleiter and Porjesz 1999; 
Rodriguez Holguin et al. 1999). 
 One of the most consistent electrophysiological 
fi ndings in alcoholics and their offspring is a lower 
amplitude P300 (P3) waveform of the event-elated 
potential (ERP) (Porjesz et al 1998a). This phe-
nomenon is also observed in individuals with other 
disinhibitory conditions such as conduct disorder, 
anti-social personality disorder and attention defi -
cit hyperactivity disorder (Cappadocia et al. 2009; 
Szuromi et al. 2011). 
 Low response to alcohol 
 A low alcohol response (LR) is a frequently observed 
phenomenon in which affected and many  “ at risk ” 
individuals require more than the usual amounts of 
alcohol in order to experience the desired alcohol 
effects (Enoch et al. 2003). Native Americans and 
Koreans, two groups with high rates of alcohol use 
disorders, appear to be more likely to have a low LR 
to alcohol early in life and prior to developing alco-
holism (Ehlers et al. 1999; Wall et al. 1999). LR is 
genetically infl uenced as shown by twin studies that 
in platelets and increased responsiveness of the pitu-
itary beta-endorphin system to alcohol challenges 
that met all of the criteria. The exploration of the 
serotonin transporter and endorphin systems includes 
the GABA and adenylyl cyclase (AC) systems. 
Numerous reports implicate cAMP-dependent pro-
tein kinases (PKA) and cAMP responsive element 
binding proteins (CREB) in alcohol dependence and 
tolerance. The attenuation of CsF  –  or forskolin-stim-
ulated platelet AC activity (Menninger et al. 2000) 
and a quantitative decrease of type 1 AC mRNA 
(Sohma et al. 1999) were also reported in alcoholic 
patients. These factors are also considered as mark-
ers for lifetime prevalence of alcohol dependence. 
Recently, a higher alcohol preference has been found 
in female type 7 AC knockout mice, which is consis-
tent with the fi ndings of type 7 AC polymorphism 
and its lower expression levels in female alcoholic 
patients (Desrivieres et al. 2011). 
 Neuroimaging studies 
 Imaging studies have shown that chronic alcohol 
intake is accompanied by volume reductions of grey 
and white matter, as well as microstructural disrup-
tion of various white matter tracts (B ü hler and 
Mann 2011). Distinctively impaired brain functions 
are associated with volume loss in several key regions 
such as the hippocampus, in which the visuospatial 
and learning/memory functions are localized (Pfef-
ferbaum et al. 1995; Sullivan et al. 1995; Agartz 
et al. 1999). Furthermore, alcohol abuse was associ-
ated with a functionally disordered brain reward 
system including subcortical striatopallidal and 
extended amygdala. Craving for alcohol leads to 
functional activation of the amygdala in recently 
studied abstinent alcoholic patients (Schneider et al. 
2001). The volume of the amygdala has been 
reported to be smaller in chronic alcoholics than in 
controls (Wrase et al. 2008; Fein et al. 2009). Sub-
cortical volume was found to be less in patients with 
a comorbid psychiatric diagnosis than controls 
(Sameti et al. 2011). Behavioural problems, includ-
ing externalizing disorders, anxiety disorders and 
mood disorders followed by substance abuse can be 
related to structural abnormalities of the amygdale, 
hippocampus, nucleus accumbens, putamen and 
thalamus (Sullivan et al. 2005; Benegal et al. 2007; 
Makris et al. 2008). In addition, most neurocogni-
tive studies have focused on testing for specifi c char-
acteristics in adolescents and young adults (e.g., 
impulsivity, risk-taking, and novelty-seeking) that 
might be impaired in groups at-risk for alcoholism, 
particularly adolescents with a family history of 
alcoholism (Schweinsburg et al. 2004). From a cog-
nitive neuroscience perspective, adolescence is a 
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 Disease aetiology: ancestry and geography 
 Genetic research has contributed considerably to the 
understanding of the aetiology and natural history of 
all health problems and diseases and their worldwide 
distribution partly refl ects both ancestral and geo-
graphic variations. In the case of alcohol use behav-
iours, the gene coding for aldehyde dehydrogenase, 
 ALDH2 * 2 , is known to protect against heavy drink-
ing and alcohol dependence that characterizes some 
Asian populations. Variations in disease prevalence 
are due to differences in population composition by 
race and ethnicity, as well as differences in geo-
graphic location. Environmental factors, including 
health care access, family and neighbourhood envi-
ronments, social relationships, and other factors also 
infl uence both health and disease prevalence. 
 Genetic traits 
 Genetic traits in humans are either simple or com-
plex. Simple genetic traits depend on variations in a 
single gene, cf. Huntington ’ s disease and cystic fi bro-
sis, in which a single gene mutation alters or destroys 
a particular biological function. However, single gene 
disorders are quite rare in the human population and 
are often observed in less than one in fi ve thousand 
individuals. Complex genetic traits are infl uenced by 
both genetic and environmental factors. Most com-
monly, these traits have multiple gene infl uences 
where variations in one gene infl uence the risk for 
developing a disease by interacting with other genes 
and/or the environment. Complex genetic traits are 
common in the human population, for example, 
heart disease, Alzheimer ’ s disease, and diabetes. 
 Psychiatric disorders, including alcohol use disor-
ders, are also considered to be complex traits, with 
many pathways leading to their development. The 
prevalence of alcohol use disorders among biological 
family members is high, with more than 80% of 
patients having at least one fi rst- or second-degree 
affected relatives. Genetic and other psychological 
and environmental factors (which can also be passed 
between generations) are likely to be involved in the 
development of a mental disorder in an affected indi-
vidual. While genetic infl uences are clearly important 
in determining susceptibility for alcohol use disorders, 
genetic and other biological factors alone cannot fully 
explain a person ’ s vulnerability for developing an 
alcohol use disorder or alcohol-related problems. 
 Genetic studies of alcohol use disorders 
 Several sources, including basic laboratory research, 
family studies, and molecular genetic studies provide 
evidence for the genetic basis of alcohol use disorders 
indicate that genetics accounts for 60% of the vari-
ance of risk for this characteristic (Heath et al. 1999; 
Viken et al. 2003). Many ( ∼ 40%) offspring of alco-
holics also have a low response to alcohol before 
they engage in heavy drinking; a low LR early in life 
is a good predictor of later heavy drinking and alco-
hol problems (Pollock 1992; Schuckit et al. 1996, 
2000). Currently, the best assessment of LR is 
through subjective testing following alcohol use. LR 
as measured by a retrospective questionnaire that 
records the number of drinks typically needed for a 
range of effects is also both genetically infl uenced 
and a good predictor of future alcohol problems. 
The search for the genes underlying LR is under-
way. Candidate genes related to the serotonin trans-
porter,  GABA A receptor, adenylyl cyclase, and 
potassium channels are being considered. Recently, 
polymorphisms in  CYP2E1 , a gene involved in alco-
hol metabolism, and  GABRG1 , which encodes the 
GABA A receptor  γ -1 subunit, have been linked to 
the response to alcohol (Ray and Hutchison 2009; 
Webb et al. 2011). 
 Others 
 The ratio of the lengths of the second and fourth 
fi nger of the right hand (smaller 2D:4D ratio) have 
been investigated in alcohol-dependent patients 
(Casey and Jones 2010). The variation of 2D:4D is 
reported to be related to the (CAG)n tri-nucleotide 
repeat found within the coding region of the andro-
gen receptors (Manning et al. 2003). Low 2D:4D 
is known to be associated with psychological traits 
such as physical aggression, novelty seeking and 
higher dominance  – features frequently reported as 
possible predictors of substance abuse (Addison 
and Kurtz 1986; Wills et al. 1994; Williams et al. 
2003). A signifi cant association is also reported 
between the (CAG)n tri-nucleotide repeat and crav-
ing for alcohol in male patients during withdrawal 
(Lenz et al. 2009). 
 Genetics and alcohol use behaviours 
 A signifi cant genetic infl uence exists in most psychi-
atric disorders and accounts for the high frequency 
of a positive family history seen in these patients. 
Recent advances in genetic technologies are rapidly 
expanding the understanding of the mechanisms by 
which genes infl uence the onset and course of alco-
hol use behaviour, including dependence. As more 
genetic information becomes available, its clinical 
application will expand and more health care provid-
ers will be able to use the information in their clini-
cal practice. 
558        E. Hashimoto et al. 
various psychiatric conditions and related traits. For 
example, the  GABRA2 gene is associated with con-
duct disorder, antisocial personality disorder, alco-
hol dependence and other drug dependencies (Dick 
et al. 2007). These results validate the model pro-
posed by Kendler and colleagues that many complex 
traits/psychiatric disorders are infl uenced by a clus-
ter of genes that are common to several related psy-
chiatric conditions (Kendler et al. 2003). As part of 
COGA, Edenberg et al. (2006) found that some 
genes are associated with more severe alcoholism, 
including an early age of onset of drinking and the 
development of alcohol dependence and more severe 
symptoms, and also to conduct problems. 
 Copy number variations (CNVs) have also been 
examined for their role in alcohol dependence 
susceptibility. A recent report by the Study of 
Addiction: Genetics and Environment (SAGE) 
investigators (2011) has identifi ed CNVs in 6q14.1 
( P    1.04    10   6 ) and 5q13.2 ( P    3.37    10   4 ) as 
being highly signifi cantly associated with alcohol 
dependence after adjusting for multiple testing. On 
chromosome 5q13.2, there were multiple candidate 
genes previously associated with various neurologi-
cal disorders. This same region on chromosome 
6q14.1 has also been associated with mental retar-
dation and language delay. 
 To date, the use of genome-wide association stud-
ies (GWAS) of alcohol dependence and related 
problems has had limited scientifi c impact because 
extremely large samples are required to satisfy the 
statistical power requirements of such studies. A suc-
cessful study typically requires pooling multiple data 
sets from different investigators and often, different 
populations. Consequently, insuffi cient phenotypic 
information is available to test complex traits related 
to a diagnosis. Rather, only simple phenotypes, such 
as average alcohol consumption, can be tested. 
A report by Schumann et al. (2011) using a com-
bined sample of approximately 26316 subjects of 
European descent drawn from 12 different studies, 
identifi ed a single nucleotide polymorphism (SNP) 
in the autism susceptibility gene  AUST2 as being 
associated with alcohol consumption. 
 Gene – environment interplay 
 There is a rapidly growing literature from twin stud-
ies and other investigations documenting how spe-
cifi c environmental factors may moderate the impact 
of genetic effects on alcohol use behaviours and 
alcohol dependence. An important example of gene-
environment interaction by Heath et al. (1989) dem-
onstrated that genetic infl uences on alcohol use were 
greater among unmarried women, whereas having a 
marriage-like relationship reduced the impact of 
(Ducci et al. 2008; Enoch 2012). Studies of the 
genetic causes of both medical and behavioural dis-
orders begin with establishing whether genetic infl u-
ences are involved. Evidence for this depends on 
studies of the pedigrees of large and multigenera-
tional families, fraternal and identical twins, or of 
persons who were adopted at an early age and raised 
apart from their biological parents in a different fam-
ily environment. Each of these methods has strongly 
suggested a role for genetic infl uences in susceptibil-
ity to alcohol use disorders. Once the familial/genetic 
nature of the trait is established through these stud-
ies, how the disorder is transmitted across genera-
tions and the strength of the genetic infl uence 
can then be investigated. Each participant (affected 
individual and family members) is interviewed, 
including a standardized diagnostic assessment for 
phenotyping purposes, and a tissue sample (blood or 
saliva) is obtained. Linkage studies are then con-
ducted to identify chromosomal regions, followed by 
association studies to identify specifi c genes. The 
function of each identifi ed gene (functional genom-
ics) can then be studied to better determine the 
possible genetic or biological mechanisms that link 
the gene to the trait of interest (Nurnberger and 
Bierut 2007). 
 The Collaborative Study of the Genetics of 
Alcoholism (COGA) 
 One of the best examples of a genetic study of alco-
hol use behaviours, including alcohol dependence, 
the Collaborative Study of the Genetics of Alcohol-
ism (COGA), is funded by the US National Insti-
tutes of Health (NIH). Beginning in 1989, it is a 
multi-site national study, currently involving 11 sites. 
COGA uses an extended family pedigree design and 
has collected data from over 12,000 adults and 4,500 
children and adolescents representing over 1,900 
families. The primary goal of the COGA project is 
to characterize the familial distribution of alcohol 
dependence within families and to identify vulnera-
bility genes for alcohol dependence and related con-
ditions using genetic linkage and association methods. 
To date, more than 25 different genes have been 
identifi ed that are associated with alcohol depen-
dence and related conditions (Table II). 
 These genes are known to have roles in the differ-
ent neurotransmitter systems, alcohol metabolism, 
sensitivity to the effects of alcohol, or taste prefer-
ence. Most of these genes are associated with an 
increased risk for alcohol dependence, but some are 
protective. From both the literature and Table II, it 
has become clear that few genes predispose to only 
a single condition. Few genes are trait specifi c, but 
more often genes contribute to the predisposition to 
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 Table II. Vulnerability genes for alcohol dependence and related conditions using genetic linkage and association methods in 
COGA studies. 
Genetic location Encoded protein function
Linked to other traits
 gene effect
 ADH4 
 Chromosome 4
Alcohol dehydrogenase; alcohol 
metabolizing enzyme
None 
 Increased risk
 ALDH2 
 Chromosome 12
Aldehyde dehydrogenase; 
 aldehyde metabolizing enzyme
None
 Protective
 CHRM2 
 Chromosome 7
Muscarinic acetylcholine receptor M2; 
 regulates neural signalling
Major depression; drugs
 Increased risk
 DRD2/ANNK1 
 Chromosome 11
Dopamine D2 receptor; 
 regulates reward reinforcement
Habitual smoking
 Increased risk
 GABRG3 
 Chromosome 15
GABAa receptor g3 subunit; 
 regulates neural signalling
Drug dependence, CD
 Increased risk
 GABRA2 
 Chromosome 4
GABAa receptor a2 subunit; 
 regulates neural signalling
Drugs; CD, ASPD
 Increased Risk
 GABRA1 
 Chromosome 5
GABAa receptor a1 subunit; 
 regulates neural signalling
Drinking patterns
 HTAS2R16 
 Chromosome 4
hTAS2R16 receptor; 
 contributes to bitter taste sensitivity
Increased drinking
 Increased risk
 HTAS38R 
 Chromosome 4
hTAS2R16 receptor; 
 contributes to bitter taste sensitivity
Heavy consumption
 Increased risk
 CHRNA5 
 Chromosome 15
Nicotinic acetylcholine receptor; 
nACHr modulated by ethanol
Alcohol, Tobacco Dependence
 Increased risk
 CHRNA3 
 Chromosome 15
Nicotinic acetylcholine receptor; nACHr 
modulated by ethanol
Nicotine Dependence
 Increased risk
 ADH1A/ADH1B 
 Chromosome 4
Alcohol dehydrogenase; 
 alcohol metabolizing enzyme
None
 Increased Risk
 CNR1; 
 Chromosome 6
Cannabinoid receptor 1: 
 regulates dopamine reward system
Cannabis dependence
 Increased risk
 OPRK1; 
 Chromosome 8
Kappa opiod receptor 1; 
 regulates neural signalling
None
 Increased risk
 PDYN 
 Chromosome 20
Kappa opiod receptor 1; 
 regulates neural signalling
Alcohol Dependence
 Increased risk
 POMC 
 Chromosome 2
Adrenocorticotropic hormone Opiod dependence
 Increased risk
 PENK 
 Chromosome 8
Proenkephalin Opiod dependence
 Increased risk
 OPRL1 
 Chromosome 20
Opiate receptor-like Opiod dependence
 NPY2R/NPY5R; 
 Chromosome 4
Neuropeptide Y receptors; 
 anxiolytic regulation
Alcohol Dep  & Withdrawal
 Increased risk
 NFKB1 
 Chromosome 4
Transcription factor NF-  B-1; 
 regulates neural signalling
Alcohol Dependence
 Increased risk
 CRHR1 
 Chromosome 17
Corticotropin releasing hormone receptor VP3 amplitude; alcohol dependence
 Increased risk
 TACR3 
 Chromosome 4
Tachykinin receptor 3 Alcohol dependence; cocaine dependence
 Increased risk
 GRM8 
 Chromosome 7
Glutamate receptor, metabotropic Alcohol dependence; ERO
 Increased risk
 ACN9 
 Chromosome 17
ACN9 homologue ( S. cerevisiae ) Alcohol dependence; ERO
 Increased risk
 SNCA 
 Chromosome 4
Synuclein, alpha Alcohol craving
 Increased risk
 SLC6A4 
 Chromosome 17 
Solute carrier family 6 (serotonin transporter) Depression
 Increased risk
genetic infl uences on drinking. Dick et al. (2006b) 
have reported that both  GABRA2 and marital status 
contribute independently to the development of 
alcohol dependence. The high-risk genotype at 
 GABRA2 was also related to a decreased likelihood 
of marrying and an increased likelihood of divorce, 
which appeared to be mediated in part by personal-
ity characteristics. There was also a differential risk 
for alcohol dependence associated with the  GABRA2 
genotype according to marital status. A similar inter-
action has been shown with social support, in gen-
eral, and the  GABRA2 genotype (Pescosolido et al. 
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subject ’ s age of onset of alcoholism (Arias et al. 
2012). 
 Whenever sharing genetic information, the clini-
cian must ensure that the patient understands that 
for complex trait disorders, genetic susceptibility is 
not absolute and that much of the heritable compo-
nent of chronic disease remains to be discovered. 
Common questions from patients include: How 
much risk do I actually have? What treatments might 
work best for me? What is my long-term prognosis? 
It is important for patients to understand that even 
complete knowledge of genetic susceptibility factors 
will not totally determine the risk for developing a 
disorder, as many cases are due to non-genetic fac-
tors and are labelled  “ sporadic cases ” . A patient ’ s 
own responsibility and accountability are vital fac-
tors in managing the patient ’ s risks and symptoms. 
 The prospects of biomarkers for alcoholics 
in the future 
 Studies of state markers are best conducted in ani-
mal or other model organisms, such as inbred mice, 
because genetic and environmental factors that infl u-
ence alcohol-related traits can better be manipulated 
under controlled environmental and genetic condi-
tions. If animal models are available, improved stud-
ies of specifi c alcohol-related endophenotypes (e.g., 
alcohol preference, sensitivity, tolerance, and depen-
dence) will advance scientifi c progress. Endopheno-
types can help improve our understanding of the 
aetiology of the endophenotype and provide a means 
for identifying which genetic factors might be most 
fruitful to study in humans. Several inbred mice lines 
have been widely used in mapping quantitative trait 
loci (QTL) for certain endophenotypes. These 
selected lines differ with respect to various alcohol-
related traits and the genes that contribute to differ-
ences in the alcohol response. 
 Alcoholic consumption varies depending on mouse 
strains; some strains have a tendency to readily con-
sume alcohol and demonstrate alcohol-related phys-
ical symptoms. Animal models of addiction can be 
organized within the stages of the addiction cycle, 
including: binge/intoxication, withdrawal/negative 
affect (anxiety-like responses, conditioned place 
aversion, elevated reward thresholds, withdrawal-
induced increases in drug self-administration), and 
preoccupation/anticipation (drug-induced reinstate-
ment, cue-induced reinstatement, stress-induced 
reinstatement) (Koob 2012). These models have 
the possibility to provide insights into the neurobio-
logical mechanisms of addiction. However, it is pos-
sible that the mouse model does not accurately 
refl ect the human condition. Further, the diverse 
2008). Religious beliefs have also been shown to 
moderate genetic infl uences on alcohol use among 
females, with genetic factors playing a larger role 
among individuals without a religious upbringing 
(Koopmans et al. 1999). 
 The importance of genetic infl uences on alcohol 
use can also vary as a function of neighbourhood and 
socio-regional factors such as urban/rural residency, 
neighbourhood stability, and regional alcohol sales 
(Dick et al. 2001; Rose et al. 2001). Genetic infl u-
ences on adolescent substance abuse appear enhanced 
in environments with less parental monitoring (Dick 
et al. 2007b) and in the presence of substance-using 
friends (Dick et al. 2007c). Genetic and environ-
mental risks for substance use disorders typically do 
not only add together, but also interact with each 
other, during development (Kendler 2012). In sum-
mary, there are a number of environmental factors, 
across a variety of different domains that moderate 
the importance of genetic infl uences on patterns of 
alcohol use. With respect to alcohol use, it appears 
that environments permitting greater opportunity to 
express genetic predispositions, as exemplifi ed by 
environments with low parental monitoring and 
high(er) peer alcohol use, are important moderators 
of genetic effects. 
 Using genetic information in clinical practice 
 Genetic information can be used in many ways to 
improve clinical practice, although genetic testing 
and the implications of sharing genetic information 
raise several issues and concerns. In the future, using 
information from a patient ’ s genome, clinicians will 
be able to predict whether a client is likely to develop 
a disease and, if he does, to make an early diagnosis. 
Further, patients will be able to receive personalized 
treatment and prevention strategies based on his/her 
genetic profi le. 
 Genetic screening is presently available for several 
diseases including breast cancer, Huntington ’ s dis-
ease, and Alzheimer ’ s disease; however, to date, no 
specifi c screening is available for psychiatric disor-
ders. Any screening test needs to be accurate (i.e. 
have both sensitivity and specifi city) to be useful, but 
the nature of complex gene disorders limits the 
application of a reliable screening test. Recently, 
pharmacogenetic analyses of treatments for alcohol 
dependence have attempted to predict treatment 
response and side-effect risk for specifi c medications. 
Variation in the  DRD4 gene, which encodes the dop-
amine D4 receptor, is suggested to predict better 
response to naltrexone and olanzapine. A polymor-
phism in the serotonin transporter gene  SLC6A4 
promoter region has been related to differential 
treatment response to sertraline, depending on the 
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behaviours, and possibly other psychiatric condi-
tions. Efforts are underway to identify genes that 
contribute to each of these and other intermediate 
phenotypes. Additionally, it will be important to 
understand how the phenotypes/endophenotypes 
and multiple related genes correlate and interact with 
environmental and cultural forces to enhance or 
diminish the risk for alcoholism. 
 An ultimate (and implicit) goal of the work 
described in this article is to develop more effective 
prevention techniques. Increased understanding of 
the biological mechanisms and genetic impact asso-
ciated with a specifi c type of increased vulnerability 
to alcoholism could enhance prevention efforts in 
several ways. For instance, children at high risk for 
developing alcohol-related problems, including chil-
dren of alcoholics, could be screened to determine 
if their risk is likely to operate through LR, external-
izing behaviours, or other phenomena, such as cog-
nitive/neurophysiological processes. This information 
may then be used to suggest which specifi c environ-
mental or cultural factors enhance the risk for a spe-
cifi c mechanism and, more importantly, identify 
those factors that might diminish the risk. Armed 
with these data, more focused and effective preventa-
tive trials can be developed. 
 An equally important goal is to expand our under-
standing of data which might enhance the evaluation 
of existing treatments and the development of new 
therapeutic approaches for alcohol use disorders. 
The more that is known about the specifi c neuro-
chemical systems that contribute to alcoholism, the 
better our ability to develop new and more effective 
pharmacologic and behavioural approaches to help 
alcoholics recover. 
 Finally, researchers should further develop the 
markers described here and seek new biomarkers. 
These fi ndings will contribute to a stronger basis for 
clinical care and a more objective assessment of alco-
hol consumption and possibly the genetic predispo-
sition to alcohol use disorders. 
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 Since blood sampling is routinely done for annual 
health check-ups, plasma biomarkers would be ideal 
for identifying alcohol-related conditions. To identify 
plasma biomarkers, proper procedures are essential 
to eliminate unnecessary blood components (e.g. 
albumin) and to isolate some fractions in which nec-
essary component(s) are enriched. However, the 
great differences in concentrations and the vast num-
ber of plasma protein constituents make it almost 
impossible to directly identify plasma biomarkers for 
alcoholism, even with high throughput techniques. 
 Conclusions 
 The search for optimal biomarkers of alcohol con-
sumption (state) and for the genetic predisposition 
toward alcohol dependence (trait) continues. 
Although currently used state markers are of some 
value, their limitations and weaknesses justify the 
continued search for more sensitive and specifi c 
markers. 
 The importance of a marker ’ s precision, accuracy, 
sensitivity, and specifi city cannot be overstated. 
Although it is unlikely that researchers will fi nd a 
single marker to satisfy all clinical needs, they may 
eventually develop combinations of markers for spe-
cifi c clinical purposes, from unselective screening 
(i.e. drinking versus not drinking) to confi rming a 
suspicion of alcohol abuse or dependence. 
 Like most human behaviours, alcohol consump-
tion patterns are aetiologically and phenotypically 
complex. Clinicians often need to detect patterns of 
drinking other than the chronic, heavy drinking pat-
terns revealed by GGT, AST, ALT, and CDT. For 
example, clinicians may need to know whether a per-
son has been drinking recently or the type of drink-
ing that has occurred (e.g. heavy or social drinking). 
Therefore, fi nding new biomarkers that measure the 
many different aspects of alcohol consumption will 
vastly improve the clinician ’ s ability to manage alco-
hol-related problems 
 In addition, the ability to study in-depth the mul-
tiple factors that contribute to the development of 
 “ alcoholism ” will depend on creating more homoge-
neous subgroups by use of endophenotypes or other 
complex phenotypic models. This can be achieved 
through the development of new classifi cation sche-
mes based on genetic/biological, physiological, and 
behavioural factors, including alcohol-metabolizing 
enzymes, neurophysiological waveforms, a low level 
of response to alcohol, externalizing or disinhibited 
562        E. Hashimoto et al. 
 Dick  DM ,  Jones  K ,  Saccone  N ,  Hinrichs  A ,  Wang  JC , et al .  2006b . 
 Endophenotypes successfully lead to gene identifi cation: results 
from the collaborative study on the genetics of alcoholism . 
 Behav Genet  36 : 112 – 126 . 
 Dick  DM ,  Aliev  F ,  Saccone  S ,  Hinrichs  A ,  Wang  JC , et al .  2007 . 
 A systematic SNP screen to fi ne-map alcohol dependence 
genes on chromosome 7 in the collaborative study on the genet-
ics of alcoholism (COGA) sample .  Behav Genetics  37 : 748 . 
 Dick  DM ,  Edenberg  HJ ,  Xuei  X ,  Goate  A ,  Kuperman  S , et al . 
 2004 .  Association of GABRG3 with alcohol dependence .  Alco-
hol Clin Exp Res  28 : 4 – 9 . 
 Dillie  KS ,  Mundt  M ,  French  MT ,  Fleming  MF .  2005 .  Cost-
benefi t analysis of a new alcohol biomarker, carbohydrate defi -
cient transferrin, in a chronic illness primary care sample . 
 Alcohol Clin Exp Res  29 : 2008 – 2014 . 
 Dolman  JM ,  Hawkes  ND .  2005 .  Combining the audit question-
naire and biochemical markers to assess alcohol use and risk 
of alcohol withdrawal in medical inpatients .  Alcohol Alcohol 
 40 : 515 – 519 . 
 Ducci  F ,  Goldman  D .  2008 .  Genetic approaches to addiction: 
genes and alcohol .  Addiction.  103 : 1414 – 1428 . 
 Edenberg  HJ ,  Dick  DM ,  Xuei  X ,  Tian  H ,  Almasy  L , et al .  2004 . 
 Variations in GABRA2, encoding the alpha 2 subunit of the 
GABA(A) receptor, are associated with alcohol dependence 
and with brain oscillations .  Am J Hum Genet  74 : 705 – 714 . 
 Edenberg  HJ ,  Xuei  X ,  Chen  HJ ,  Tian  H ,  Wetherill  LF , et al .  2006 . 
 Association of alcohol dehydrogenase genes with alcohol 
dependence: a comprehensive analysis .  Hum Mol Genet 
 15 : 1539 – 1549 . 
 Ehlers  CL ,  Garcia  AC ,  Wall  TL ,  Cloutier  D ,  Phillips  E .  1999 .  Elec-
troencephalographic responses to alcohol challenge in Native 
American Mission Indians .  Biol Psychiatry  15 : 776 – 787 . 
 Enoch  MA .  2012 .  The infl uence of gene-environment interactions 
on the development of alcoholism and drug dependence .  Curr 
Psychiatry Rep  14 : 150 – 158 . 
 Enoch  MA ,  Schuckit  MA ,  Johnson  BA ,  Goldman  D .  2003 . 
 Genetics of alcoholism using intermediate phenotypes .  Alcohol 
Clin Exp Res  27 : 169 – 176 . 
 Fein  G ,  Shimotsu  R ,  Chu  R ,  Barakos  J .  2009 .  Parietal gray 
matter volume loss is related to spatial processing defi cits in 
long-term abstinent alcoholic men .  Alcohol Clin Exp Res 
 33 : 1806 – 1814 . 
 Feinman  JA ,  Dunner  DL .  1996 .  he effect of alcohol and substance 
abuse on the course of bipolar affective disorder .  J Affect Dis-
ord  37 : 43 – 49 . 
 Finn  PR .  2002 .  Motivation, working memory, and decision mak-
ing: a cognitive-motivational theory of personality vulnerability 
to alcoholism .  Behav Cogn Neurosci Rev  1 : 183 – 205 . 
 Fleming  M ,  Bhamb  B ,  Schurr  M ,  Mundt  M ,  Williams  A .  2009 . 
 Alcohol biomarkers in patients admitted for trauma .  Alcohol 
Clin Exp Res  33 : 1777 – 1781 . 
 Fleming  M ,  Brown  R ,  Brown  D .  2004 .  The effi cacy of a brief 
alcohol intervention combined with %CDT feedback in 
patients being treated for type 2 diabetes and/or hypertension . 
 J Stud Alcohol  65 : 631 – 637 . 
 Flint  J ,  Munafo  MR .  2007 .  The endophenotype concept in psy-
chiatric genetics .  Psychol Med  37 : 163 – 180 . 
 Gonz á lez-Ill á n  F ,  Ojeda-Torres  G ,  D í az-V á zquez  LM ,  Rosario  O . 
 2011 .  Detection of fatty acid ethyl esters in skin surface lipids 
as biomarkers of ethanol consumption in alcoholics, social 
drinkers, light drinkers, and teetotalers using a methodology 
based on microwave-assisted extraction followed by solid-phase 
microextraction and gas chromatography-mass spectrometry . 
 J Anal Toxicol  35 : 232 – 237 . 
 Hayes  GA ,  Templer  DI ,  Jansen  MA ,  Graham  CR .  1989 .  Alcohol-
ism: abstinence, improvement, and no improvement in general 
population .  Adv Alcohol Subst Abuse  8 : 87 – 96 . 
development, identifi cation and utilization of 
alcohol biomarkers, they do not have fi nancial 
confl icts of interest to declare in relation to devel-
opment of this manuscript. 
 References 
 Addison  WR ,  Kurtz  DT .  1986 .  Nucleotide sequences required 
for the regulation of a rat alpha 2u-globulin gene by gluco-
corticoids .  Mol Cell Biol  6 : 2334 – 2346 . 
 Agartz  I ,  Momenan  R ,  Rawlings  RR ,  Kerich  MJ ,  Hommer  DW . 
 1999 .  Hippocampal volume in patients with alcohol depend-
ence .  Arch Gen Psychiatry  56 : 356 – 363 . 
 Arias  AJ ,  Sewell  RA .  CNS  Drugs .  2012 .  Pharmacogenetically 
driven treatments for alcoholism: are we there yet?  CNS Drugs 
 26 : 461 – 476 . 
 Atkinson  RM ,  Ryan  SC ,  Turner  JA .  2001 .  Variation among again 
alcoholic patients in treatment .  Am J Geriatr Psychiatry  9 :
 275 – 282 . 
 B ü hler  M ,  Mann  K .  2011 .  Alcohol and the human brain: a sys-
tematic review of different neuroimaging methods .  Alcohol 
Clin Exp Res  35 : 1771 – 1793 . 
 Babor  TF ,  Kranzler  HR ,  Lauerman  RJ .  1989 .  Early detection of 
harmful alcohol consumption: comparison of clinical, labora-
tory, and self-report screening procedures .  Addict Behav 
 14 : 139 – 157 . 
 Barr  CS ,  Schwandt  M ,  Lindell  SG ,  Chen  SA ,  Goldman  D , et al . 
 2007 .  Association of a functional polymorphism in the mu-
opioid receptor gene with alcohol response and consumption 
in male rhesus macaques .  Arch Gen Psychiatry  64 : 369 – 376 . 
 Begleiter  H ,  Porjesz  B .  1999 .  What is inherited in the predisposi-
tion toward alcoholism? A proposed model .  Alcohol Clin Exp 
Res  23 : 1125 – 1135 . 
 Benegal  V ,  Antony  G ,  Venkatasubramanian  G ,  Jayakumar  PN . 
 2007 .  Gray matter volume abnormalities and externalizing 
symptoms in subjects at high risk for alcohol dependence . 
 Addict Biol  12 : 122 – 132 . 
 Cappadocia  MC ,  Desrocher  M ,  Pepler  D ,  Schroeder  JH .  2009 . 
 Contextualizing the neurobiology of conduct disorder in an 
emotion dysregulation framework .  Clin Psychol Rev  29 :
 506 – 518 . 
 Casey  BJ ,  Jones  RM .  2010 .  Neurobiology of the adolescent brain 
and behavior: implications for substance use disorders .  J Am 
Acad Child Adolesc Psychiatry  49 : 1189 – 1201 . 
 Cheema  ZF ,  West  JR ,  Miranda  RC .  2000 .  Ethanol induces Fas/
Apo [apotosis]-1 mRNA and cell suicide in the developing cer-
ebral cortex .  Alcohol Clin Exp Res  24 : 535 – 543 . 
 Chen  J ,  Conigrave  KM ,  Macaskill  P ,  Whitfi eld  JB ,  Irwig  L .  2003 . 
 Combining carbohydrate-defi cient transferrin and gamma-
glutamyltransferase to increase diagnostic accuracy for problem 
drinking .  Alcohol Alcohol  38 : 574 – 582 . 
 Conigrave  KM ,  Davies  P ,  Haber  P ,  Whitfi eld  JB .  2003 .  Traditional 
markers of excessive alcohol use .  Addiction  98 : 31 – 43 . 
 Cornelius  JR ,  Bukstein  O ,  Salloum  I ,  Clark  D .  2003 .  Alcohol and 
psychiatric comorbidity .  Recent Dev Alcohol  16 : 361 – 374 . 
 D’Souza  DC ,  Gil  RB ,  Madonick  S ,  Perry  EB ,  Forselius  BK , 
et al .  2006 .  Enhanced sensitivity to the euphoric effects 
of alcohol in schizophrenia .  Neuropsychopharmacology  31 : 
2767 – 2775 . 
 Desrivieres  S ,  Pronko  SP ,  Lourdusamy  A ,  Ducci  F ,  Hoffman  PL , 
et al .  2011 .  Sex-specifi c role for adenylyl cyclase type 7 in alco-
hol dependence .  Biol Psychiatry  69 : 1100 – 1108 . 
 Dick  DM ,  Aliev  F ,  Bierut  L ,  Goate  A ,  Rice  J , et al .  2006a .  Link-
age analyses of IQ in the collaborative study on the genetics of 
alcoholism (COGA) sample .  Behav Genet  36 : 77 – 86 . 
  Biological markers for alcoholics        563
of alcohol dependence. WHO/ISBRA Collaborative Study 
Investigators. International Society for Biomedical Research on 
Alcoholism .  Alcohol Clin Exp Res  24 : 810 – 821 . 
 Miller  PM ,  Spies  C ,  Neumann  T ,  Javors  MA ,  Hoyumpa  AM , 
et al .  2006 .  Alcohol biomarker screening in medical and surgi-
cal settings .  Alcohol Clin Exp Res  30 : 185 – 193 . 
 Nurnberger  JIJ ,  Bierut  LJ .  2007 .  Seeking the connections: alcohol-
ism and our genes .  http://www.sciam.com/article.cfm?id    seek-
ing-the-connections-alcoholism-and-our-genes 
 Nyblom  H ,  Berggren  U ,  Balldin  J ,  Olsson  R .  2004 .  High AST/
ALT ratio may indicate advanced alcoholic liver disease rather 
than heavy drinking .  Alcohol Alcohol  39 : 336 – 339 . 
 Ohkawa  H ,  Sohma  H ,  Sakai  R ,  Kuroki  Y ,  Hashimoto  E , et al . 
 2002 .  Ethanol-induced augmentation of annexin IV in cultured 
cells and the enhancement of cytotoxicity by overexpression of 
annexin IV by ethanol .  Biochim Biophys Acta  1588 : 217 – 225 . 
 Pescosolido  BA ,  Perry  BL ,  Scott Long  J ,  Martin  JK .  2008 . 
 Under the infl uence of genetics: how transdisciplinarity leads 
us to rethink social pathways to illness .  Am J Sociol  114(Suppl) :
 S171 – 201 . 
 Peterson  K .  2004 – 2005 .  Biomarkers for alcohol use and abuse – a 
summary .  Alcohol Res Health  28 : 30 – 37 . 
 Pfefferbaum  A ,  Sullivan  EV ,  Mathalon  DH ,  Shear  PK , 
 Rosenbloom  MJ ,  Lim  KO .  1995 .  Longitudinal changes in mag-
netic resonance imaging brain volumes in abstinent and 
relapsed alcoholics .  Alcohol Clin Exp Res  19 : 1177 – 1191 . 
 Pollock  VE .  1992 .  Meta-analysis of subjective sensitivity to alco-
hol in sons of alcoholics .  Am J Psychiatry  149 : 1534 – 1538 . 
 Porjesz  B ,  Begleiter  H ,  Reich  T ,  Van Eerdewegh  P ,  Edenberg  HJ , 
et al .  1998a .  Amplitude of visual P3 event-related potential 
as a phenotypic marker for a predisposition to alcoholism: 
preliminary results from the COGA Project. Collaborative 
Study on the Genetics of Alcoholism .  Alcohol Clin Exp Res 
 22 : 1317 – 1323 . 
 Porjesz  B ,  Begleiter  H ,  Reich  T ,  Van  EP ,  Edenberg  HJ , et al . 
 1998b .  Amplitude of visual P3 event-related potential as a phe-
notypic marker for a predisposition to alcoholism: preliminary 
results from the COGA Project. Collaborative Study on the 
Genetics of Alcoholism .  Alcohol Clin Exp Res  22 : 1317 – 1323 . 
 Ratsma  JE ,  Van Der Stelt  O ,  Gunning  WB .  2002 .  Neurochemical 
markers of alcoholism vulnerability in humans .  Alcohol Alcohol 
 37 : 522 – 533 . 
 Ray  LA ,  Hutchison  KE .  2009 .  Associations among GABRG1, 
level of response to alcohol, and drinking behaviors .  Alcohol 
Clin Exp Res  33 : 1382 – 1390 . 
 Regier  DA ,  Farmer  ME ,  Rae  DS ,  Locke  BZ ,  Keith  SJ , et al .  1990 . 
 Comorbidity of mental disorders with alcohol and other drug 
abuse. Results from the Epidemiologic Catchment Area (ECA) 
Study .  J Am Med Assoc  264 : 2511 – 2518 . 
 Rodriguez Holguin  S ,  Porjesz  B ,  Chorlian  DB ,  Polich  J , 
 Begleiter  H .  1999 .  Visual P3a in male alcoholics and controls . 
 Alcohol Clin Exp Res  23 : 582 – 591 . 
 Saito  M ,  Saito  M ,  Berg  MJ ,  Guidotti  A ,  Marks  N .  1999 .  Ganagl-
iosides attenuate ethanol-induced apoptosis in rat cerebellar 
granule neurons .  Neurochem Res  24 : 1107 – 1115 . 
 Sameti  M ,  Smith  S ,  Patenaude  B ,  Fein  G .  2011 .  Subcortical vol-
umes in long-term abstinent alcoholics: associations with psy-
chiatric comorbidity .  Alcohol Clin Exp Res  35 : 1067 – 1080 . 
 Schneider  F ,  Habel  U ,  Wagner  M ,  Franke  P ,  Salloum  JB , et al . 
 2001 .  Subcortical correlates of craving in recently abstinent 
alcoholic patients .  Am J Psychiatry  158 : 1075 – 1083 . 
 Schuckit  MA .  1986 .  Biological markers in alcoholism .  Prog Neu-
ropsychopharmacol Biol Psychiatry  10 : 191 – 199 . 
 Schuckit  MA .  1999 .  New fi ndings in the genetics of alcoholism . 
 J Am Med Assoc  26 : 1875 – 1876 . 
 Schuckit  MA ,  Smith  TL ,  Kalmijn  J ,  Tsuang  J ,  Hesselbrock  V , 
 Bucholz  K .  2000 .  Response to alcohol in daughters of alcoholics: 
 Heath  AC ,  Madden  PA ,  Bucholz  KK ,  Dinwiddie  SH ,  Slutske  WS , 
et al .  1999 .  Genetic differences in alcohol sensitivity and the 
inheritance of alcoholism risk .  Psychol Med  29 : 1069 – 1081 . 
 Helander  A ,  P é ter  O ,  Zheng  Y .  2012 .  Monitoring of the alcohol 
biomarkers PEth, CDT and EtG/EtS in an outpatient treat-
ment setting .  Alcohol Alcohol [Epub ahead of print]. 
 Hermansson  U ,  Helander  A ,  Huss  A ,  Brandt  L ,  Ronnberg  S . 
 2000 .  The Alcohol Use Disorders Identifi cation Test (AUDIT) 
and carbohydrate-defi cient transferrin (CDT) in a routine 
workplace health examination .  Alcohol Clin Exp Res  24 :
 180 – 187 . 
 Hietala  J ,  Koivisto  H ,  Anttila  P ,  Niemela  O .  2006 .  Comparison 
of the combined marker GGT-CDT and the conventional 
laboratory markers of alcohol abuse in heavy drinkers, moder-
ate drinkers and abstainers .  Alcohol Alcohol  41 : 528 – 533 . 
 Hines  LM ,  Ray  L ,  Hutchison  K ,  Tabakoff  B .  2005 .  Alcoholism: 
the dissection for endophenotypes .  Dialogues Clin Neurosci 
 7 : 153 – 163 . 
 Hoefer  P ,  Syeda  B ,  Bergler  KJ ,  Friedrich  F ,  Lesch  OM , et al . 
 2011 .  Amino-terminal pro-B-type brain natriuretic Peptide: 
screening for cardiovascular disease in the setting of alcoholism . 
 Alcohol Alcohol  46 : 247 – 252 . 
 Isaksson  A ,  Walther  L ,  Hansson  T ,  Andersson  A ,  Alling  C .  2011 . 
 Phosphatidylethanol in blood (B-PEth): a marker for alcohol 
use and abuse .  Drug Test Anal  3 : 195 – 200 . 
 Jellinek  EM .  1960 .  Alcoholism, a genus and some of its species . 
 Can Med Assoc J  83 : 1341 – 1345 . 
 Kendler  KS ,  Prescott  CA ,  Myers  J ,  Neale  MC .  2003 .  The struc-
ture of genetic and environmental risk factors for common 
psychiatric and substance use disorders in men and women . 
 Arch Gen Psychiatry  60 : 923 – 937 . 
 Kendler  KS ,  Chen  X ,  Dick  D ,  Maes  H ,  Gillespie  N ,  Neale  MC , 
 Riley  B .  2012 .  Recent advances in the genetic epidemiology 
and molecular genetics of substance use disorders .  Nat Neuro-
sci  15 : 181 – 189 . 
 Koob  GF .  2012 .  Animal models of psychiatric disorders .  Handb 
Clin Neurol  106 : 137 – 166 . 
 Kumari  M ,  Ticku  MK .  2000 .  Regulation of NMDA receptors by 
ethanol .  Prog Drug Res  54 : 152 – 189 . 
 Lamy  S ,  Thibaut  F .  2011 .  Biological markers of exposure of 
foetus to alcohol during pregnancy . In  Hoffman  JD ,  editor . 
 Pregnancy and Alcohol Consumption. Public Health in the 
21st century. Ch 15 .  New York, NY: Nova Science Publishers, 
Inc ; 2011. p  347 – 358 . 
 Lapham  SC ,  C’de Baca  J ,  McMillan  G ,  Hunt  WC .  2004 .  Accu-
racy of alcohol diagnosis among DWI offenders referred for 
screening .  Drug Alcohol Depend  76 : 135 – 141 . 
 Le Fauve  CE ,  Litten  RZ ,  Randall  CL ,  Moak  DH ,  Salloum  IM , 
 Green  AI .  2004 .  Pharmacological treatment of alcohol abuse/
dependence with psychiatric comorbidity .  Alcohol Clin Exp 
Res  28 : 302 – 312 . 
 Lenz  B ,  Jacob  C ,  Frieling  H ,  Jacobi  A ,  Hillemacher  T , et al .  2009 . 
 Polymorphism of the long polyglutamine tract in the human 
androgen receptor infl uences craving of men in alcohol with-
drawal .  Psychoneuroendocrinology  34 : 968 – 971 . 
 Makris  N ,  Oscar  BM ,  Jaffi n  SK ,  Hodge  SM ,  Kennedy  DN , et al . 
 2008 .  Decreased volume of the brain reward system in alcohol-
ism .  Biol Psychiatry  64 : 192 – 202 . 
 Mann  K ,  Kiefer  F ,  Smolka  M ,  Gann  H ,  Wellek  S ,  Heinz  A .  2009 . 
 Searching for responders to acamprosate and naltrexone in 
alcoholism treatment: rationale and design of the PREDICT 
study .  Alcohol Clin Exp Res  33 : 674 – 683 . 
 Manning  TJ ,  Bundred  EP ,  Newton  JD ,  Flanagan  FB .  2003 .  The 
second to fourth digit ratio and variation in the androgen 
receptor gene .  Evol Hum Behav  24 : 399 – 405 . 
 Menninger  JA ,  Baron  AE ,  Conigrave  KM ,  Whitfi eld  JB ,  Saunders 
 JB , et al .  2000 .  Platelet adenylyl cyclase activity as a trait marker 
564        E. Hashimoto et al. 
 Viken  RJ ,  Rose  RJ ,  Morzorati  SL ,  Christian  JC ,  Li  TK .  2003 . 
 Subjective intoxication in response to alcohol challenge: 
heritability and covariation with personality, breath alcohol 
level, and drinking history .  Alcohol Clin Exp Res  27 :
 795 – 803 . 
 Wall  TL ,  Johnson  ML ,  Horn  SM ,  Carr  LG ,  Smith  TL , 
 Schuckit  MA .  1999 .  Evaluation of the self-rating of the effects 
of alcohol form in Asian Americans with aldehyde dehydro-
genase polymorphisms .  J Stud Alcohol  60 : 784 – 789 . 
 Webb  A ,  Lind  PA ,  Kalmijn  J ,  Feiler  HS ,  Smith  TL , et al .  2011 . 
 The investigation into CYP2E1 in relation to the level of 
response to alcohol through a combination of linkage and asso-
ciation analysis .  Alcohol Clin Exp Res  35 : 10 – 18 . 
 Williams  JHG ,  Greenhalgh  KD ,  Manning  JT .  2003 .  Second to 
fourth fi nger ratio and possible precursors of developmental 
psychopathology in preschool children .  Early Hum Dev  72 :
 57 – 65 . 
 Wills  TA ,  Vaccaro  D ,  McNamara  G .  1994 .  Novelty seeking, risk 
taking, and related constructs as predictors of adolescent sub-
stance use: an application of Cloninger’s theory .  J Subst Abuse 
 6 : 1 – 20 . 
 Winokur  G ,  Coryell  W ,  Endicott  J ,  Keller  M ,  Akiskal  H ,  Solomon 
 D .  1996 .  Familial alcoholism in manic-depressive (bipolar) dis-
ease .  Am J Med Genet  9 : 197 – 201 . 
 Wrase  J ,  Makris  N ,  Braus  DF ,  Mann  K ,  Smolka  MN , et al .  2008 . 
 Amygdala volume associated with alcohol abuse relapse and 
craving .  Am J Psychiatry  165 : 1179 – 1184 . 
 Wurst  FM ,  Kelso  E ,  Weinmann  W ,  Pragst  F ,  Yegles  M , 
 Sundstroem  PI .  2008 .  Measurement of direct ethanol metabo-
lites suggests higher rate of alcohol use among pregnant women 
than found with the AUDIT--a pilot study in a population-
based sample of Swedish women .  Am J Obstet Gynecol 
 198 : 407 . 
 Wurst  FM ,  Skipper  GE ,  Weinmann  W .  2003 .  Ethyl glucuronide–
the direct ethanol metabolite on the threshold from science to 
routine use .  Addiction  98(Suppl 2) : 51 – 61 . 
a pilot study and a comparison with sons of alcoholics .  Alcohol 
Alcohol  35 : 242 – 248 . 
 Schuckit  MA ,  Tsuang  WJ ,  Anthenelli  MR ,  Tipp  EJ , 
 Nurnberger  IJ .  1996 .  Alcohol challenges in young men from 
alcoholic pedigrees and control families: a report from the 
COGA project .  J Stud Alcohol  57 : 368 – 377 . 
 Schweinsburg  AD ,  Paulus  MP ,  Barlett  VC ,  Killeen  LA , 
 Caldwell  LC , et al .  2004 .  An FMRI study of response inhibi-
tion in youths with a family history of alcoholism .  Ann NY 
Acad Sci  1021 : 391 – 394 . 
 Sogawa  K ,  Kodera  Y ,  Satoh  M ,  Kawashima  Y ,  Umemura  H , et al . 
 2011 .  Increased serum levels of pigment epithelium-derived 
factor by excessive alcohol consumption-detection and identi-
fi cation by a three-step serum proteome analysis .  Alcohol Clin 
Exp Res  35 : 211 – 217 . 
 Sohma  H ,  Hashimoto  E ,  Shirasaka  T ,  Tsunematsu  R ,  Ozawa  H , 
et al .  1999 .  Quantitative reduction of type I adenylyl cyclase in 
human alcoholics .  Biochim Biophys Acta  1454 : 11 – 18 . 
 Sorbi  D ,  Boynton  J ,  Lindor  KD .  1999 .  The ratio of aspartate 
aminotransferase to alanine aminotransferase: potential value 
in differentiating nonalcoholic steatohepatitis from alcoholic 
liver disease .  Am J Gastroenterol  94 : 1018 – 1022 . 
 Spies  CD ,  Kissner  M ,  Neumann  T ,  Blum  S ,  Voigt  C , et al .  1998 . 
 Elevated carbohydrate-defi cient transferrin predicts prolonged 
intensive care unit stay in traumatized men .  Alcohol Alcohol 
 33 : 661 – 669 . 
 Sullivan  EV ,  Deshmukh  A ,  De  RE ,  Rosenbloom  MJ ,  Pfefferbaum 
 A .  2005 .  Striatal and forebrain nuclei volumes: contribution to 
motor function and working memory defi cits in alcoholism . 
 Biol Psychiatry  57 : 768 – 776 . 
 Sullivan  EV ,  Marsh  L ,  Mathalon  DH ,  Lim  KO ,  Pfefferbaum  A . 
 1995 .  Anterior hippocampal volume defi cits in nonamnesic, 
aging chronic alcoholics .  Alcohol Clin Exp Res  19 : 110 – 122 . 
 Szuromi  B ,  Czobor  P ,  Komlosi  S ,  Bitter  I .  2011 .  P300 defi cits in 
adults with attention defi cit hyperactivity disorder: a meta-
analysis .  Psychol Med  41 : 1529 – 1538 . 
